Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am really liking my CLNE investment and option call.. Can't help but get excited :)
Fuck! almost hit 0.50 over the weekend but the chances are we are prolly hitting it this week..
Whoa! It’s at 0.4364 earlier.. I am beginning to get super excited..lol
Fuck yeah! 0.50 is inching away..
A decent day today for WPRT up 7.26% atm..
It's a decent day both CLNE and WPRT today.. I am not really kissing my money goodbye because my CLNE position both long and option call are looking good Jack.I am so glad I added when people were panicking and I will be glad more a year from now and beyond..
A complete turn around from up 24% to down 2% atm..
Hoping 700 scripts or better will come in next week..
Do you have the numbers for this week Sid? TIA
Elvis has left the building I mean ALL-IN :)
Bring on the $5! GO TEUM!
I did look at TPNL but I haven't done any readings.. You should look at CLNE and read their last earnings I really think this quarter is the last chance to get them cheapies..
GO TEUM!
It's a great time to own shares especially with these few PRs that came out last week and today's.. This is the type of company that I usually look for when I invest with great fundamental and potential.. Cheers
That's funny I didn't even know you existed.. Actually my co-worker told me about TEUM..
1 week chart shows from 0.2237 to 0.3087 that's 33.84% gain not too shabby eh..
Oh I see you already got your pom pom there ALL-IN888 :)
Oh shit my $4.40 buy starts to look puuuuuurty... GO TEUM!
We were missing your cheerleading this am :) Nice buy tho..
I currently own these cryptos/blockchain BTC, NEO, ETH, IOTA, XRP, ETN, & BAT.. I tell you guys what, BAT is what I am very excited about..
$0.311 printing..
World is evolving Jack and whether you like it or not electric/clean energy will going to replaced diesel.. The writing is on the wall
With $72M win contract for their past 2 PRs TEUM this should be around $6-$7s by now.. MMs are definitely scooping all the cheap shares and once they have enough they will let this run hard..
$0.3062 printing.. BAT has a power like a redBULL energy drink :)
It's definitely a good time to own shares as we continue to see the upside trend.. In my opinion will hit 0.50 sooner than later
MannKind files $500M mixed shelf, warrant exercise prospectus
Mar. 29, 2019 5:50 PM ET|About: MannKind Corporation (MNKD)|By: Jason Aycock, SA News Editor
MannKind (NASDAQ:MNKD) has filed a $500M mixed shelf registration to offer up to that amount in any combination of common stock, preferred stock, debt securities and warrants.
The filing also has a warrant exercise prospectus to cover up to 26.7M shares.
The warrants covered by that prospectus are the 2018 Common Warrants issued on Dec. 26, exercisable at a price of $1.60 any time before Dec. 26, 2019.
Shares are currently down 2% after hours, to $1.93.
Smoking hot today.. Wonder what's the reason of a big move today? GO ACRX!
0.2882 printing...you sold too soon masahirox..
$0.2644 now
Without them crooks TEUM should of gained at least 0.50 on today's news..SMH
After hours news..This is great
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of He...
Print
Alert
Dynavax Technologies Corp. (NASDAQ:DVAX)
Intraday Stock Chart
Today : Thursday 28 March 2019
Click Here for more Dynavax Technologies Corp. Charts.
Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has accepted the Company's Marketing Authorization Application (MAA) for review of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
This acceptance follows Dynavax's submission of the MAA on March 11 and marks the beginning of the regulatory review process for HEPLISAV-B in the European Union (EU). The outcome of the MAA review by the EMA is expected next year.
"The acceptance of the HEPLISAV-B application for review by the EMA signifies an important milestone in our journey to help prevent hepatitis B in adults through vaccination," said Robert Janssen, M.D., chief medical officer of Dynavax. "Many at-risk adults remain unprotected against this highly infectious virus. HEPLISAV-B has been shown to provide higher rates of protection with fewer doses than currently available vaccines. We hope to make HEPLISAV-B available beyond the U.S. to help address the global hepatitis B public health problem."
In 2017, the U.S. Food and Drug Administration (FDA) approved HEPLISAV-B for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B was the first new hepatitis B vaccine in the U.S. in more than 25 years and the only two-dose hepatitis B vaccine for adults.
The MAA for HEPLISAV-B is based upon the successful outcomes from three Phase 3 non-inferiority trials of nearly 10,000 adult participants who received HEPLISAV-B. The pivotal studies compared HEPLISAV-B administered in two doses over one month to Engerix-B administered in three doses over a six-month schedule. Results from the largest Phase 3 trial, which included 6,665 participants, showed that HEPLISAV-B demonstrated a statistically significantly higher rate of protection of 95% compared with 81% for Engerix-B. Across the three clinical trials, the most common local reaction was injection site pain (23% to 39%). The most common systemic reactions were fatigue (11% to 17%) and headache (8% to 17%).
About Hepatitis B
Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death. The hepatitis B virus is 50 to 100 times more infectious than HIV,i and transmission is on the rise. There is no cure for hepatitis B, but effective vaccination can prevent the disease.
In adults, hepatitis B is spread through contact with infected blood and through unprotected sex with an infected person. The CDC recommends vaccination for those at high risk for infection due to their jobs, lifestyle, living situations and travel to certain areas.ii
About HEPLISAV-B
HEPLISAV-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax’s proprietary Toll-like Receptor (TLR) 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV-B.
For more information about HEPLISAV-B, visit http://heplisavb.com/.
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Forward-Looking Statements
This press release contains "forward-looking" statements, including statements regarding HEPLISAV-B and the potential timing of an EMA review decision. These statements are subject to a number of risks, including whether the EMA will find the submission to be complete or whether it will seek further information, including the conduct of additional clinical trials; whether it will complete its review of the MAA within the anticipated timeframe; and whether the outcome of its review will be an approval, as well as other risks detailed in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.
Contact:
Heather Rowe
Vice President, Investor Relations & Corporate Communications
hrowe@dynavax.com
510-665-7269
___________________________________________________
Awesome!!!! Already up over 100% in my first buy at 0.12
Not a chance with that PR they put out this am..
I am not day trading this stock..Fundamentally speaking looks great so I am treating this as an investment..
Flying under the radar.. Give TEUM a week or two and it will hit a 52 week high
My buys from yesterday was perfect timing.. Good contract...NICE!
Woohoo even my 0.19 buys a couple of weeks ago starts to look good..
Potential is huge on ACRX especially if it becomes the SOC...
No doubt this is a good long term hold..
I doubt all-in there's no reason to bring that low fact as you look at the chart I think its forming a new base for a higher run.. TEUM is as bullish as fhuck! lol
Awesome for us who got in this early as BAT's pps continue to climb..
Ah I finally got my shares at $4.40.. I wish I had bought at $4.30ish but wanted the dust to settled.. MMs can now let 'er rip.
Nice article from SA btw..
Meanwhile my $3 option call for Sept 20 is looking great..
I asked you how high do you think it will go a couple of days ago but I got zipped from you..
Didn't I tell you that MMs will bring down to $4.30ish and fill the gaps but you told me that I should learn how read a chart..lol